June 5, 2019
InSysBio announces their participation at PAGE 2019 28th Meeting being held from 11 to 14 June 2019 in Stockholm, Sweden. InSysBio is presenting five posters:
Wednesday, June 12 (9:50-11:15):
Wednesday, June 12 (15:10-16:40):
Thursday, June 13 (9:55-11:20):
Thursday, June 13 (15:25-16:50):
IV-74: “Amyloid ? in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects” (view abstract) by Tatiana Karelina
V-89: “Application of different approaches to generate virtual patient populations for QSP model of physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies” (view abstract) by Galina Kolesova, Oleg Demin, Evgeny Metelkin and Dmitry Shchelokov
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit insysbio.com.
| ← | December 2019 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Dec 2019 15:35
InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting
QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
